Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Which salad do you believe is a definitive group pleaser? Vote! - 2Kiefer Sutherland arrested after allegedly assaulting a ride-share driver in L.A.
- 3Defence chiefs of Thailand and Cambodia to discuss ceasefire
- 4The Most Notable Design Brands of the 21st Hundred years
- 5A mom stopped giving her kids snacks — and sparked a debate about eating habits
- Bombardier Global 8000 Enters Service
- Vote in favor of the Web-based Work out schedule to Keep You Fit and Sound
- Historical mysteries solved by science in 2025
- Council removes proposal to rename park named after former president of Israel
- An Extended time of Careful Nurturing: Individual Bits of knowledge on Bringing up Youngsters
- How to watch ‘The Traitors’ U.K. Season 4 from the U.S.
- Nodding off is dangerous. Some animals have evolved extreme ways to sleep in precarious environments
- Warning for snow and ice extended
- Marvel's X-Men are joining the battle in 'Avengers: Doomsday': Watch the teaser
